One Stop Shop For Reports One Stop Shop For Reports
  • All Reports
  • All Sectors
    • Chemicals & Materials
      • Advanced Materials
      • Bulk Chemicals
      • Coatings | Paints and Additives
      • Composites
      • Renewable | Speciality chemicals
    • Consumer Goods
      • Baby Products
      • Consumer Electronics
      • Consumer Packaging
      • Cosmetics & Personal Care
      • Homecare & Decor
      • Luxury & premium products
    • Energy and Power
      • Energy Efficiency and Conservation
      • Green | Renewable Energy
      • Non Renewable | Conventional Energy
      • Power Equipment and Devices
    • Life Science
      • Biotechnology
      • Diagnostics
      • Healthcare
      • Healthcare IT
      • Medical Devices & Supplies
      • Pharmaceuticals
    • Food and Beverage
      • Agriculture & Agri Products
      • Beverages
      • Food Ingredients
      • Food Services and Hospitality
      • Nutraceutical | Wellness Food
      • Processed & Frozen Foods
    • Automotive and Transportation
      • Automotive components
      • Automotive Logistics
      • Automotive systems and accessories
    • Information and Communications Technology
      • E Commerce and Outsourcing
      • Entertainment & Media
      • High Tech | Enterprise & Consumer IT
      • Information & Network Security
      • Mobility | Telecom & Wireless
      • Software and Services
    • Semiconductor and Electronics
      • Semiconductor Materials and Components
      • Display Technology
      • Electronics System and Components
      • Emerging technologies
      • Security and Surveillance
      • Sensors and Controls
    • Building and Construction
      • Construction Materials
      • HVAC
      • Residential Construction and Improvement
      • Roads & Highways
    • Manufacturing
      • Manufacturing Services
      • Heavy Manufacturing
      • Packaging
      • Engineering | Equipment and Machinery
  • Who Trust Us
  • [email protected]
  • +1 718 874 1545 (International)
  • +91 78878 22626 (Asia)

More Results

One Stop Shop For Reports One Stop Shop For Reports
  • All Reports
  • All Sectors
    • Chemicals & Materials
      • Advanced Materials
      • Bulk Chemicals
      • Coatings | Paints and Additives
      • Composites
      • Renewable | Speciality chemicals
    • Consumer Goods
      • Baby Products
      • Consumer Electronics
      • Consumer Packaging
      • Cosmetics & Personal Care
      • Homecare & Decor
      • Luxury & premium products
    • Energy and Power
      • Energy Efficiency and Conservation
      • Green | Renewable Energy
      • Non Renewable | Conventional Energy
      • Power Equipment and Devices
    • Life Science
      • Biotechnology
      • Diagnostics
      • Healthcare
      • Healthcare IT
      • Medical Devices & Supplies
      • Pharmaceuticals
    • Food and Beverage
      • Agriculture & Agri Products
      • Beverages
      • Food Ingredients
      • Food Services and Hospitality
      • Nutraceutical | Wellness Food
      • Processed & Frozen Foods
    • Automotive and Transportation
      • Automotive components
      • Automotive Logistics
      • Automotive systems and accessories
    • Information and Communications Technology
      • E Commerce and Outsourcing
      • Entertainment & Media
      • High Tech | Enterprise & Consumer IT
      • Information & Network Security
      • Mobility | Telecom & Wireless
      • Software and Services
    • Semiconductor and Electronics
      • Semiconductor Materials and Components
      • Display Technology
      • Electronics System and Components
      • Emerging technologies
      • Security and Surveillance
      • Sensors and Controls
    • Building and Construction
      • Construction Materials
      • HVAC
      • Residential Construction and Improvement
      • Roads & Highways
    • Manufacturing
      • Manufacturing Services
      • Heavy Manufacturing
      • Packaging
      • Engineering | Equipment and Machinery
  • Who Trust Us
Home ➤ Life Science ➤ Pharmaceuticals ➤ Antibody Drug Conjugates Market
Antibody Drug Conjugates Market
Antibody Drug Conjugates Market
Published date: Sept 2023 • Formats:
Request Sample Schedule a Call
  • Home ➤ Life Science ➤ Pharmaceuticals ➤ Antibody Drug Conjugates Market

Global Antibody Drug Conjugates Market, By Product (Adcetris, Kadcyla, and Other Product Types), By Application (Blood Cancer, Breast Cancer, Ovary Cancer, and Other Applications) By End User (Hospitals and Speciality Cancer Centers, Biotechnology and Pharmaceutical Companies, and Other End Users), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032

  • Published date: Sept 2023
  • Report ID: 102579
  • Number of Pages: 373
  • Format:
  • Overview
  • Table of Contents
  • Major Market Players
  • Request a Free Sample
  • Quick Navigation

    • Report Overview
    • Key Takeaways
    • Application Analysis
    • Technology Analysis
    • Product Analysis
    • End-User Analysis
    • Key Market Segments
    • Drivers
    • Restraints
    • Opportunity
    • Trends
    • Regional Analysis
    • Key Players Analysis
    • Recent Developments
    •  Report Scope

    Report Overview

    In 2022, the global Antibody Drug Conjugates Market accounted for USD 7.2 billion and is expected to grow to around USD 34.7 billion in 2032. Between 2023 and 2032, this market is estimated to register the highest CAGR of 17.5%.

    The market is mainly driven by an increase in cancer incidences globally. ADCs are intended to deliver a cytotoxic payload directly to cancer cells while sparing healthy cells, making treatment more focused, efficient, and with fewer side effects. A monoclonal antibody, a cytotoxic substance, and a linker that joins the to make up an ADC.

    A particular antigen on the surface of cancer cells is recognized and bound to by the monoclonal antibody. The cancer cell internalizes the ADC once it has been bonded, and the cytotoxic chemical is then released, leading to cell death. Because of the lack of health insurance coverage, the number of patient visits decreases in hospitals, and the COVID-19 pandemic harmed product sales. The possible approval of ADCs like Adcetris for other applications was delayed due to the lack of participants in clinical trial trials.

    Antibody Drug Conjugates Market

    *Actual Numbers Might Vary In The Final Report

    Key Takeaways

    • Market Growth: The global Antibody Drug Conjugates (ADCs) market was valued at USD 7.2 billion in 2022 and is expected to reach USD 34.7 billion by 2032, with a CAGR of 17.5% between 2023 and 2032.
    • Cancer Incidences: Increasing cancer cases worldwide are a major driver of the ADC market. ADCs deliver cytotoxic payloads directly to cancer cells while sparing healthy cells, making treatment more focused and efficient.
    • Application Analysis: Breast cancer treatment occupies the largest market share due to the rising approvals of ADCs for breast cancer. Blood cancer treatment is also expected to have a significant market presence.
    • Technology Analysis: Cleavable linkers dominate the market due to their stability in the bloodstream and controlled cytotoxin release. This technology is expected to continue to grow.
    • Product Analysis: Non-cleavable linkers, like Kadcyla for breast cancer, are on the rise. These linkers provide high stability for antigen-negative cells.
    • End-User Analysis: Hospitals and specialty cancer centers are the primary end-users of ADCs. They manage patient side effects and ensure appropriate treatment.
    • Market Drivers: Technological advancements, rising cancer prevalence, government support for cancer research, and expanding healthcare systems are driving market growth.
    • Restraints: High production costs, side effects, and challenges in production, such as raw material costs and skilled labor, are restraining factors.
    • Opportunities: Increased government involvement in cancer prevention and treatment, along with public and private sector collaborations, offers growth opportunities.
    • Trends: ADCs are increasingly used in cancer treatment due to their targeted approach, and the FDA has approved several ADCs. The market is expected to revive after the COVID-19 pandemic.
    • COVID-19 Impact: The pandemic led to decreased revenue due to fewer patient visits and diagnosis rates. However, post-pandemic, increased adoption of modern medical procedures is expected.
    • Regional Analysis: North America dominates with a 40.0% market share, driven by rising healthcare expenses. Europe follows, with increasing cancer prevalence.
    • Key Players: Major companies are focusing on growth strategies like product development, approvals, and mergers & acquisitions to enhance their market presence.

    Application Analysis

    The largest market share for global antibody drug conjugates derives from the breast cancer category. Breast glandular tissue is where breast cancer, a non-transmissible illness, develops. The World Health Organization (WHO) estimates that 2.3 million women will receive a breast cancer diagnosis. The expansion of this market is being driven by the increasing number of approvals for antibody-drug conjugates that can be used to treat breast cancer.

    Throughout the forecast period, the blood cancer sector is anticipated to occupy a sizable proportion of the market. Blood cancer, the fifth most frequent malignancy, has a variety of different forms and affects the blood cells. Leukaemia and lymphoma have both been more common in recent years.

    Technology Analysis

    The cleavable linker segment dominated the market with a greater market share. Cleavable linkers are the most widely utilized technology to improve the effectiveness of ADCs in the treatment of cancer because they can stay secure in the bloodstream for a longer period and release cytotoxin from ADCs.

    For instance, the Chinese National Medical Products Administration (NMPA) approved the use of Seagen & Takeda’s Adcetris in 2020 for the therapy for relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma (sALCL). Throughout the forecast period, these factors are anticipated to propel the cleavable linker market segment.

    Product Analysis

    The non-cleavable linker segment is expanding due to the fast-rising Kadcyla usage. The non-cleavable linker technology-based antibody-drug conjugate used in the treatment of breast cancer is called Kadcyla. The projection term is expected to see a strong increase in the non-cleavable linker sector. High-stability non-cleavable linkers aid in the death of antigen-negative cells. The medication Adcetris, which is used to treat Hodgkin lymphoma and systemic anaplastic large cell lymphoma, comprises the active ingredient brentuximab vedotin. It functions by locating and eliminating cancer cells.

    Antibody Drug Conjugates Market Share

    End-User Analysis

    Based on end-user, the Hospitals, and Speciality Cancer Centers segment dominate the global antibody drug conjugates market with the largest revenue share. Patients that require specific therapy are given ADCs by hospitals and specialized cancer clinics. To achieve this, it is necessary to manage any side effects or adverse reactions, as well as to make sure that patients are given the appropriate amount of the ADC and are responding to treatment as expected.

    Key Market Segments

    Based on Product

    • Adcetris
    • Kadcyla
    • Other Product Types

    Based on Application

    • Blood Cancer
    • Breast Cancer
    • Ovary Cancer
    • Lung Cancer
    • Skin Cancer
    • Brain Tumor
    • Other Applications

    Based on Technology

    • Cleavable Linker
    • Non-cleavable Linker

    Based on Target Type

    • CD30 Antibodies
    • HER2 Antibodies
    • Other Target Types

    Based on End-User

    • Hospitals and Speciality Cancer Centers
    • Biotechnology and Pharmaceutical Companies
    • Other End Users

    Drivers

    Technological advancements

    The first-generation ADCs’ limited success (developed in the early 2000s) paved the way for second-generation ADCs to enter the global antibody drug conjugates market (from 2010 onwards). These ADCs have higher levels of cytotoxic drug conjugation, lower levels of naked antibodies, and more stable linkers between the drug and the antibody. Nevertheless, Third-generation ADCs (2019 and later) use site-specific conjugation techniques in place of random coupling, enabling rigorous control over payload conjugation to produce a homogenous result.

    Increasing prevalence of cancer

    Cancer incidence grows with age due to a rise in the risk of certain tumors as people get older. When a person gets older, cellular repair mechanisms become less efficient, which increases the danger. The demand for ADCs is being pulled down by the rising cancer incidence. According to GLOBOCAN 2020, there were around 10.0 million cancer-related deaths and 19.3 million new cases of cancer worldwide.

    Restraints

    High production costs

    The cost of raw materials, the use of technology, the lengthy production process, and the demand for a competent and The majority of the expense of producing antibody-drug conjugates is attributed to professional labor. Moreover, changes in the cost of resources have an impact on production costs. Companies in the biotechnology and pharmaceutical industries spend a lot of money on R&D.

    Side-effects

    ADCs have a reasonable side-effect profile due to their high selectivity, with nausea and vomiting being the most frequent toxicities. This changes, nevertheless, according to the ADC and the supplementary payload. Other side effects include stomatitis, vomiting, infection, fever, and nausea. Low blood counts, liver damage, including infusion-related reactions (IRRs), hepatic veno-occlusive disease, and bleeding are among these significant adverse effects.

    Opportunity

    Increasing the contribution of the public and commercial sectors to the fight against cancer

    Governments are motivated to engage in cancer preventive research initiatives in light of public health concerns and the continually increasing prevalence of cancer worldwide. Also, many governments in developing nations are concentrating on enhancing the healthcare system to provide cancer patients with efficient therapy. The support for the manufacture of antibody-drug conjugates will increase due to the government’s expanding engagement in cancer prevention; this will help the market’s expansion throughout the anticipated timeframe.

    Trends

    ADCs are being utilized more frequently in the treatment of cancer because they provide a targeted strategy that can increase efficacy and decrease side effects as compared to traditional chemotherapy. The FDA has approved several ADCs for the treatment of cancer, and many more are in development.

    Regional Analysis

    North America dominates the global antibody drug conjugates market with a market share of 40.0%. rising healthcare expenses and the introduction of new products are important drivers of the antibody-drug conjugates market in North America. Also, the anticipated timeframe will see an increased focus on the need for antibody-drug conjugates due to the expanding number of cancer patients.

    Europe holds the second-largest market for antibody-drug conjugates globally. The market growth in the region is a result of the increasing prevalence of cancer in European nations, which accounts for over 25% of all fatalities in the United Kingdom each year.

    Antibody Drug Conjugates Market Regional Analysis

    Key Regions

    • North America
      • US
      • Canada
    • Europe
      • Germany
      • France
      • The UK
      • Spain
      • Italy
      • Russia
      • Netherland
      • Rest of Europe
    • Asia Pacific
      • China
      • Japan
      • South Korea
      • India
      • New Zealand
      • Singapore
      • Thailand
      • Vietnam
      • Rest of APAC
    • Latin America
      • Brazil
      • Mexico
      • Rest of Latin America
    • Middle East & Africa
      • South Africa
      • Saudi Arabia
      • UAE
      • Rest of MEA

    Key Players Analysis

    The major companies are focusing on growth strategies such as product developments, new product approvals, and mergers & acquisitions to enhance their share of the worldwide antibody drug conjugates market. For instance, Immunomedics, Inc. was acquired by Gilead for D21.0 billion. Adcetris from Takeda has also been likened to China’s NMPA for the treatment of adult patients with ALCL or systemic Hodgkin lymphoma.

    Market Key Players

    • Takeda Pharmaceutical Company Limited
    • Hoffmann-La Roche Ltd.
    • Pfizer, Inc.
    • AstraZeneca
    • Gilead Sciences, Inc.
    • Astellas Pharma, Inc.
    • Seagen, Inc.
    • Daiichi Sankyo Company, Limited
    • GlaxoSmithKline plc
    • Adc Therapeutics Saa
    • ImmunoGen Inc.
    • Bayer AG
    • Novartis AG
    • Agensys Inc.
    • Concortis Biotherapeutics
    • NBE-Therapeutics
    • Spirogen
    • Oxford BioTherapeutics
    • Other Key Players

    Recent Developments

    • In June 2022: ADC Therapeutics was in the process of introducing its medication, camidanlumab tesirine, which is the second ADC, to the company’s portfolio. Phase 2 of the clinical trial for the medication produced encouraging findings. As a potential treatment for Hodgkin’s lymphoma, they are probably going to petition for FDA approval.
    • In June 2022: Spirea Limited stated that it has received GBP 2.4 million in funding from investors for the development of highly specialized ADCs for the treatment of solid tumors. Their innovation allows for a larger drug-to-antibody ratio, which increases the amount of medicine administered to the affected area to kill cancer cells. This would support the treatment of cancer in more ways.
    • In May 2022: Fam-trastuzumab deruxtecan-nxki (Enhertu), which was created to treat metastatic HER2, a form of positive breast cancer, received FDA approval for usage in May 2022. Along with AstraZeneca, Daiichi Sankyo created the medication.

     Report Scope

    Report Features Description
    Market Value (2022) USD 7.2 Billion
    Forecast Revenue (2032) USD 34.7 Billion
    CAGR (2023-2032) 17.5%
    Base Year for Estimation 2022
    Historic Period 2016-2022
    Forecast Period 2023-2032
    Report Coverage Revenue Forecast, Market Dynamics, COVID-19 Impact, Competitive Landscape, Recent Developments
    Segments Covered Product (Adcetris, Kadcyla, Other Product Types) Application (Blood Cancer, Breast Cancer, Ovary Cancer, Lung Cancer, Skin Cancer, Brain Tumor, Other Applications) Technology (Cleavable Linker, Non-cleavable Linker) Target type (CD30 Antibodies, HER2 Antibodies, Other Target Types) End-User (Hospitals and Speciality Cancer Centers, Biotechnology and Pharmaceutical Companies, Other End Users)
    Regional Analysis North America – The US, Canada, & Mexico; Western Europe – Germany, France, The UK, Spain, Italy, Portugal, Ireland, Austria, Switzerland, Benelux, Nordic, & Rest of Western Europe; Eastern Europe – Russia, Poland, The Czech Republic, Greece, & Rest of Eastern Europe; APAC – China, Japan, South Korea, India, Australia & New Zealand, Indonesia, Malaysia, Philippines, Singapore, Thailand, Vietnam, & Rest of APAC; Latin America – Brazil, Colombia, Chile, Argentina, Costa Rica, & Rest of Latin America; Middle East & Africa – Algeria, Egypt, Israel, Kuwait, Nigeria, Saudi Arabia, South Africa, Turkey, United Arab Emirates, & Rest of MEA
    Competitive Landscape Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Pfizer, Inc., AstraZeneca, Gilead Sciences, Inc., Astellas Pharma, Inc., Seagen, Inc., Daiichi Sankyo Company, Limited, GlaxoSmithKline plc, Adc Therapeutics Saa, ImmunoGen Inc., Bayer AG, Novartis AG, Agensys Inc., Concortis Biotherapeutics, NBE-Therapeutics, Spirogen, Oxford BioTherapeutics, Other Key Players

     

    Customization Scope Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements.
    Purchase Options We have three licenses to opt for Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF)

    Frequently Asked Questions (FAQ)

    What is the size of the global Antibody Drug Conjugates market?

    In 2022, the global Antibody Drug Conjugates Market accounted for USD 7.2 billion and is expected to grow to around USD 34.7 billion in 2032.

    What is the Antibody Drug Conjugates Market CAGR During the Forecast Period 2022-2032?

    The Global Antibody Drug Conjugates Market size is growing at a CAGR of 17.5% during the forecast period from 2022 to 2032.

    Who are some of the major players in the Antibody Drug Conjugates Market?

    Key players in the market include Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Pfizer, Inc., AstraZeneca, Gilead Sciences, Inc., Astellas Pharma, Inc., Seagen, Inc., Daiichi Sankyo Company, Limited, GlaxoSmithKline plc, Adc Therapeutics Saa, ImmunoGen Inc., Bayer AG, Novartis AG, Agensys Inc., Concortis Biotherapeutics, NBE-Therapeutics, Spirogen, Oxford BioTherapeutics, Other Key Players.

    Antibody Drug Conjugates Market
    Antibody Drug Conjugates Market
    Published date: Sept 2023
    add_shopping_cartBuy Now get_appDownload Sample
    keyboard_arrow_up
    • Takeda Pharmaceutical Company Limited
    • Hoffmann-La Roche Ltd.
    • Pfizer, Inc.
    • AstraZeneca Plc Company Profile
    • Gilead Sciences, Inc.
    • Astellas Pharma, Inc.
    • Seagen, Inc.
    • Daiichi Sankyo Company, Limited
    • GlaxoSmithKline plc
    • Adc Therapeutics Saa
    • ImmunoGen Inc.
    • Bayer AG Company Profile
    • Novartis AG Company Profile
    • Agensys Inc.
    • Concortis Biotherapeutics
    • NBE-Therapeutics
    • Spirogen
    • Oxford BioTherapeutics
    • Other Key Players
  • settingsSettings

Related Reports

  • Antibody Production Market
  • TCR-Based Antibody Market
  • Custom Antibody Services Market
  • Antibodies Market
  • Infection Control Market
  • Amniotic Membrane Market

Our Clients

  • Our Clients
Inquiry Before Buying

Antibody Drug Conjugates Market
  • 102579
  • Sept 2023
    • ★★★★★
      ★★★★★
    • (55)
add_shopping_cart Buy Now
Trusted by more than 17382 organizations globally
  • Client Logo
  • Client Logo
  • Client Logo
✖
Request a Sample Report
We'll get back to you as quickly as possible

Single User
$6,000
$3,999
USD / per unit
save 24%
Multi User
$8,000
$5,999
USD / per unit
save 28%
Corporate User
$10,000
$6,999
USD / per unit
save 32%
e-Access
Report Library Access
Data Set (Excel)
Print
Company Profile Library Access
Interactive Dashboard
Free Custumization No up to 10 hrs work up to 30 hrs work
Accessibility 1 User 2-5 User Unlimited
Analyst Support up to 20 hrs up to 40 hrs up to 50 hrs
Benefit Up to 20% off on next purchase Up to 25% off on next purchase Up to 30% off on next purchase
Buy Now ($ 3,999) Buy Now ($ 5,999) Buy Now ($ 6,999)
  • location_on420 Lexington Avenue, Suite 300 New York City, NY 10170,
    United States
  • phone+1 718 874 1545 (International)
  • phone+91 78878 22626 (Asia)
  • email[email protected]
  • Facebook Logo
  • Twitter Logo
  • LinkedIn Logo
Find Help
  • Contact Us
  • How to Order
Legal
  • Privacy Policy
  • Refund Policy
  • Frequently Asked Questions
  • Terms and Conditions
Explore
  • About Us
  • All Reports
  • All Sectors
  • Infographics
  • Statistics and Facts
  • Companies
Secured Payment Options
Secured Payment Options

© 2025 Market.Us. All Rights Reserved.